论文部分内容阅读
目的对晚期乳腺癌患者Survivin的表达情况及对放疗敏感性的分析。方法选取首诊并确诊为晚期乳腺癌(局部T4期)并丧失手术治疗机会的30例女性患者作为研究对象。对入组患者行TAC方案全身化疗及放疗,根据放疗敏感性进行分组,分为放疗敏感组和放疗不敏感组,比较2组放疗前后Survivin表达情况。结果 1Survivin蛋白在晚期乳腺癌患者放疗敏感组和放疗不敏感组组的高表达率分别为40%(8/20)和80.0%(8/10),两组差异具有统计学意义(P<0.05)。2放疗敏感组中Survivin表达平均值为(29.10±14.68),显著低于放疗不敏感组(46.71±15.54)(P<0.05)。3放疗敏感组和放疗不敏感组组的凋亡指数分别是(15.39±3.15)和(8.17±1.96),两组间差异显著(P<0.05)。Survivin高表达组和Survivin低表达组的凋亡指数分别是(10.23±2.33)、(14.78±1.69),两组间差异显著(P<0.05)。4放疗后,放疗敏感组Survivin表达为(20.33±7.89),与放疗前相比,差异显著(P<0.05)。放疗不敏感组为(42.48±13.87),与放疗前相比,差异无统计学意义(P>0.05)。结论 Survivin表达水平与放疗敏感性之间存在密切关系,可以作为预测乳腺癌放疗敏感性、疗效评价及预后的指标。
Objective To investigate the expression of Survivin in patients with advanced breast cancer and its sensitivity to radiotherapy. Methods Thirty female patients diagnosed with advanced breast cancer (local T4 stage) and lost the chance of surgical treatment were selected as the study subjects. Patients underwent TAC regimen chemotherapy and radiotherapy, according to the radiosensitivity were divided into radiosensitive group and radiosensitive group. The expression of Survivin before and after radiotherapy was compared between the two groups. Results The high expression rates of 1Survivin protein in patients with advanced breast cancer were 40% (8/20) and 80.0% (8/10), respectively, with significant difference between radiosensitive and radiosensitive groups (P <0.05 ). The average expression of Survivin in radiation-sensitive group was (29.10 ± 14.68), which was significantly lower than that in radiosensitive group (46.71 ± 15.54) (P <0.05). The apoptotic index of radiosensitive sensitive group and radiosensitive sensitive group were (15.39 ± 3.15) and (8.17 ± 1.96) respectively, with significant difference between the two groups (P <0.05). The apoptosis index of Survivin high expression group and Survivin low expression group were (10.23 ± 2.33) and (14.78 ± 1.69), respectively, with significant difference between the two groups (P <0.05). 4 After radiotherapy, the expression of Survivin in radiosensitive sensitive group was (20.33 ± 7.89), which was significantly different from that before radiotherapy (P <0.05). The radiosensitivity group was (42.48 ± 13.87), which was not significantly different from that before radiotherapy (P> 0.05). Conclusion There is a close relationship between the expression level of Survivin and radiosensitivity, which can be used as an index to predict the sensitivity, curative effect and prognosis of breast cancer.